1 citations,
January 2020 in “Egyptian Journal of Dermatology and Venereology” Higher testosterone and DHT levels are linked to hair loss in men, but not to prostate cancer risk.
Androgen-modulating drugs do not significantly change the heat sensitivity of prostate cancer cells.
86 citations,
March 1993 in “Toxicology and Applied Pharmacology” Finasteride affects male rat genitalia development, causing abnormalities during specific pregnancy days.
August 2017 in “Revista de la Facultad de Ciencias Médicas (Quito)/Revista de la Facultad de Ciencias Médicas” Early baldness in men may indicate a higher risk of prostate cancer.
14 citations,
March 2001 in “Psychiatric Services” Older men should openly discuss sexual health with doctors to improve their quality of life.
32 citations,
May 2006 in “The Journal of Urology” Using finasteride with TIP extends time off period for prostate cancer patients.
88 citations,
February 2008 in “Journal of Medicinal Chemistry” Scientists made the first metal-based compounds from a nonsteroidal antiandrogen drug, which showed potential in fighting both hormone-dependent and independent prostate cancer cells.
38 citations,
July 2012 in “international journal of endocrinology and metabolism” Some plant-derived compounds may help with hormonal conditions, but more research is needed to confirm their effectiveness.
January 2008 in “The Year book of endocrinology” Gene variant linked to prostate cancer, hormone levels, and hair loss.
4 citations,
December 2013 in “Archivio italiano di urologia, andrologia” Dutasteride reduces hospitalization and prostate cancer risk compared to finasteride, potentially offsetting its higher cost.
6 citations,
September 1997 in “Prostate Cancer and Prostatic Diseases” Finasteride 5 mg effectively reduces urinary symptoms and PSA levels in men with enlarged prostates, with few sexual side effects.
February 2012 in “Community oncology” The document concludes that accurately identifying leukemia types is crucial, and the risks of cancer from finasteride need careful evaluation against its benefits.
March 2012 in “Dermatology Times E-News” Men with pattern baldness may have a higher risk of prostate issues.
21 citations,
April 1998 in “Urology” Finasteride effectively treats BPH and hair loss but may cause sexual side effects.
People with early-onset hair loss (AGA) have a higher risk of heart disease, metabolic syndrome, and prostate enlargement.
93 citations,
February 2009 in “Annals of the New York Academy of Sciences” 5α‐reductase isozymes are crucial for prostate development and health, and targeting them can help prevent and treat prostate issues.
May 1999 in “Drugs & Therapy Perspectives” Finasteride helps increase or maintain hair in most men but can cause sexual side effects and should not be used by women, especially during pregnancy.
5 citations,
January 2018 in “Interdisciplinary sciences: computational life sciences” Accurate protein modeling can help develop new treatments for prostate cancer and other diseases.
109 citations,
April 2000 in “European Urology” Finasteride lowers risk of urinary issues and surgery by over 50% in 4 years.
6 citations,
January 2020 in “The Aging Male” Testosterone replacement therapy improved blood sugar and fat levels without raising prostate cancer risk in Japanese men with low testosterone.
24 citations,
February 2012 in “Prostate cancer and prostatic diseases” 5α-reductase inhibitors help shrink the prostate, improve urinary symptoms, and may reduce prostate cancer risk.
August 2017 in “Revista de la Facultad de Ciencias Médicas (Quito)/Revista de la Facultad de Ciencias Médicas” Early-onset male baldness may indicate a higher risk of prostate cancer.
March 2009 in “The Journal of Urology” Shorter PSADT after prostate surgery is linked to higher risk of death.
April 2013 in “The Journal of Urology” Higher CRP levels suggest chronic inflammation is linked to bladder-related urinary symptoms in men with enlarged prostates.
402 citations,
August 2011 in “Cancer research” Prostate cancer cells can make their own androgens to activate the androgen receptor, and treatments like abiraterone may increase this ability, suggesting new therapies should target the entire steroid-making pathway.
16 citations,
January 2003 in “Nuclear Receptor Signaling” Androgens and SARMs play a role in body mass, frailty, skin health, and hair growth, and are used in treating prostate cancer, acne, and hair loss, with potential for new uses and improved versions in the future.
24 citations,
June 2013 in “Expert opinion on pharmacotherapy” Dutasteride effectively treats benign prostatic hyperplasia but isn't approved for preventing prostate cancer.
12 citations,
February 2003 in “European Urology Supplements” Dutasteride reduces DHT more effectively than finasteride.
February 2017 in “Cancer Causes & Control” Swedish men with the E213 A-allele of the androgen receptor have a lower risk of prostate cancer.
May 2007 in “The Journal of Urology” Finasteride lowers PSA levels in men, certain factors increase testicular cancer risk, and current guidelines for penile cancer may lead to unnecessary surgeries.